CD20-directed Cytolytic Antibody [EPC]

231049 reported adverse events

Drugs of this class: OFATUMUMAB OBINUTUZUMAB OCRELIZUMAB RITUXIMAB RITUXIMAB AND HYALURONIDASE RITUXIMAB-ABBS RITUXIMAB-ARRX RITUXIMAB-PVVR UBLITUXIMAB

These side effects are most commonly reported by patients taking drugs of the CD20-directed Cytolytic Antibody [EPC] class:

#	Side effect	Count
0	DRUG INEFFECTIVE	30097
1	OFF LABEL USE	28153
2	FATIGUE	20996
3	PAIN	17357
4	RHEUMATOID ARTHRITIS	15936
5	COVID-19	15349
6	PYREXIA	12147
7	HEADACHE	12073
8	ARTHRALGIA	11372
9	INFUSION RELATED REACTION	11219

See all common reactions for CD20-directed Cytolytic Antibody [EPC]

Drugs of the CD20-directed Cytolytic Antibody [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE	3351	0.8384
1	SWOLLEN JOINT COUNT INCREASED	936	0.8225
2	PEMPHIGUS	6361	0.7804
3	SARS-COV-2 ANTIBODY TEST NEGATIVE	289	0.7707
4	RED BLOOD CELL SEDIMENTATION RATE	198	0.7645
5	RHEUMATIC FEVER	1094	0.7136
6	RHEUMATOID FACTOR POSITIVE	2467	0.6910
7	B-LYMPHOCYTE COUNT DECREASED	610	0.6689
8	DEEP VEIN THROMBOSIS POSTOPERATIVE	346	0.6641
9	CHRONIC LYMPHOCYTIC LEUKAEMIA RECURRENT	335	0.6607

See all enriched reactions for CD20-directed Cytolytic Antibody [EPC]